The EHMT2 Knockout CAL-27 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the CAL-27 human tongue squamous cell carcinoma cell line. This pool harbors targeted disruption of the EHMT2 gene, providing a mixed population for loss-of-function studies. The polyclonal format avoids single-cell cloning bottlenecks, maintaining broad representation of knockout alleles and enabling robust assessment of EHMT2-dependent phenotypes.
CAL-27 is an epithelial cell line established from a 56-year-old male patient with tongue squamous cell carcinoma. This line exhibits features of oral squamous cell carcinoma (OSCC), including invasive potential, and is widely used to study OSCC pathogenesis and therapeutics. Its adherent growth and stability make it suitable for gene editing and downstream assays.
EHMT2 (also known as G9a) encodes a histone methyltransferase that primarily catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), a hallmark of transcriptionally repressive heterochromatin. This enzyme functions within multi-protein complexes including its heterodimeric partner EHMT1 (GLP), DNA methyltransferase DNMT1, heterochromatin protein 1 (HP1) family members, and proliferating cell nuclear antigen (PCNA), thereby coupling histone methylation to DNA methylation and replication-linked chromatin assembly. EHMT2 is regulated by multiple upstream transcription factors such as HIF1A, E2F1, MYC, REST, and NF-??B, which modulate its expression in response to diverse stimuli, while post-transcriptional regulation is exerted by the miR-200 family. Its catalytic activity leads to transcriptional silencing of critical downstream targets, including the tumor suppressors CDH1 (E-cadherin), CDKN1A (p21), TP53, PTEN, DLC1, and the mesenchymal marker VIM (Vimentin). Consequently, EHMT2 functions as a key repressor of epithelial gene expression and a driver of invasive phenotypes.
In the context of CAL-27 oral squamous cell carcinoma cells, EHMT2 knockout abrogates H3K9 methylation-dependent gene silencing, releasing transcriptional repression of tumor suppressor loci. This reactivation can impair cell proliferation, migration, and invasion, as EHMT2-mediated silencing of CDH1 and CDKN1A is known to facilitate epithelial-to-mesenchymal transition (EMT) and bypass senescence barriers. The polyclonal knockout population, containing a spectrum of loss-of-function alleles, better mirrors the heterogeneity of tumor cell responses than monoclonal derivatives. Moreover, this model system enables interrogation of epigenetic dependencies and synthetic lethal interactions, offering a platform to evaluate EHMT2 inhibitors in a more physiologically relevant setting. By restoring expression of PTEN and TP53, the knockout cells may also exhibit altered sensitivity to other targeted agents.
Typical research applications include functional dissection of EHMT2 in oral squamous cell carcinoma, epigenetic regulation of gene expression, cancer cell proliferation, migration, and invasion assays, drug target validation for EHMT2 inhibitors, and investigation of histone methylation dynamics. Researchers can quantify H3K9me2 levels by Western blotting, measure re-expression of tumor suppressor genes via RT-qPCR (e.g., CDH1, CDKN1A), perform chromatin immunoprecipitation (ChIP) for H3K9me2 at gene promoters, and conduct transwell migration and invasion assays. Transcriptome profiling by RNA-seq reveals global gene expression changes upon EHMT2 disruption, while drug sensitivity assays with EHMT2 inhibitors allow therapeutic evaluation. For further information, please contact Ascent Research.
